Department of Medicine, San Filippo Neri Hospital, Neurology Unit, Rome, Italy.
Neurodegener Dis Manag. 2020 Dec;10(6):409-423. doi: 10.2217/nmt-2020-0018. Epub 2020 Oct 14.
Symptomatic treatment has a great relevance for the management of patients with neurologic diseases, since it reduces disease burden and improves quality of life. Aminopyridines (APs) are a group of potassium (K+) channel blocking agents that exert their activity both at central nervous system level and on neuromuscular junction. This review describes the use of APs for the symptomatic treatment of neurological conditions. We will describe trials leading to the approval of the extended-release 4-aminopyridine for MS and evidence in support of the use in other neurological diseases.
对症治疗对神经系统疾病患者的管理具有重要意义，因为它可以减轻疾病负担并提高生活质量。氨基吡啶类（APs）是一组钾（K+）通道阻断剂，它们在中枢神经系统水平和神经肌肉接头处都发挥作用。本综述描述了 APs 在神经系统疾病的对症治疗中的应用。我们将描述导致延长释放 4-氨基吡啶获批用于 MS 的试验，并提供支持其在其他神经系统疾病中应用的证据。
